Ordering
Available Variants1 mg
CHA.98479-1mg
Price
€154.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mg | CHA.98479-1mg | €154.40 |
≥95% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C119H212N46O26 · xC2HF3O2 |
|---|---|
| CAS Number | 1507930-54-2 |
| Molecular Weight | 2703.25 (free base basis) |
| NACRES | NA.77 |
| UNSPSC Code | 12352200 |
| Assay | ≥95% (HPLC) |
| Form | lyophilized powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
TAT-Gap19 trifluoroacetate salt, with a CAS number of 1507930-54-2, is a synthetic peptide derivative that has garnered significant attention in the realm of cardiovascular research. This compound is a modified version of the peptide known as TAT-Gap19, which is designed to selectively target and inhibit the activity of certain ion channels in the cardiovascular system. The trifluoroacetate salt form of TAT-Gap19 is often utilized in experimental settings to enhance the solubility and stability of the peptide, thereby facilitating its administration and bioavailability in various research models. Studies have demonstrated the potential of TAT-Gap19 trifluoroacetate salt to modulate cardiovascular function and provide therapeutic benefits in certain disease states, highlighting its promise as a novel pharmacological agent for the treatment of cardiovascular disorders. Further research is necessary to fully elucidate its mechanisms of action and potential clinical applications.
